title: Prognostic relevance of LGALS3BP in human colorectal carcinoma.
abstract: BACKGROUND
  A previous report has shown that LGALS3BP (also known as 90K or Mac-2 BP) has antitumor activity in colorectal cancer (CRC) via suppression of Wnt signalling with a novel mechanism of ISGylation-dependent ubiquitination of β-catenin. The role of LGALS3BP in CRC prognosis was investigated.
  
  
  METHODS
  The role of LGALS3BP on CRC progression and clinical prognosis was analyzed by combining cell cultures, in vitro assays, and immunohistochemistry.
  
  
  RESULTS
  Silencing of LGALS3BP in HCT-116 human colon cancer cells resulted in enhanced β-catenin expression that was reversed by addition of human recombinant LGALS3BP. Moreover, intra-tumor delivery of LGALS3BP reduced tumor growth of xenografts originating from LGALS3BP-silenced HCT-116 cells. Finally, in a series of 196 CRC patients, LGALS3BP expression in tumor tissue associated with clinical outcome. Patients with high LGALS3BP expression had lower risk of relapse and a longer overall survival time than those with low LGALS3BP expression. Multivariate analyses confirmed LGALS3BP expression status as the only independent prognostic factor of survival.
  
  
  CONCLUSIONS
  These results provide evidence that low expression of LGALS3BP participates in malignant progression of CRC and implicates poor prognosis, highlighting its augmentation as a potential therapeutic approach.
authors.affiliation: MediaPharma s.r.l., Via dei Vestini, 31, Chieti, Italy. e.piccolo@unich.it.
authors.forename: Enza
authors.initials: E
authors.lastname: Piccolo
authors.affiliation: MediaPharma s.r.l., Via dei Vestini, 31, Chieti, Italy. ntinari@unich.it.|Department of Experimental and Clinical Sciences, "G. D'Annunzio" University and Foundation, Chieti, Italy. ntinari@unich.it.
authors.forename: Nicola
authors.initials: N
authors.lastname: Tinari
authors.affiliation: Department of Experimental and Clinical Sciences, "G. D'Annunzio" University and Foundation, Chieti, Italy. domedaddario@tiscali.it.
authors.forename: Domenica
authors.initials: D
authors.lastname: D'Addario
authors.affiliation: Department of Experimental and Clinical Sciences, "G. D'Annunzio" University and Foundation, Chieti, Italy. c.rossi@unich.it.
authors.forename: Cosmo
authors.initials: C
authors.lastname: Rossi
authors.affiliation: Department of Ob/Gyn, University la Sapienza, Rome, Italy. vale.iacobelli@gmail.it.
authors.forename: Valentina
authors.initials: V
authors.lastname: Iacobelli
authors.affiliation: MediaPharma s.r.l., Via dei Vestini, 31, Chieti, Italy. rossanalasorda@gmail.com.
authors.forename: Rossana
authors.initials: R
authors.lastname: La Sorda
authors.affiliation: Department of Experimental and Clinical Sciences, "G. D'Annunzio" University and Foundation, Chieti, Italy. rossanolattanzio@libero.it.
authors.forename: Rossano
authors.initials: R
authors.lastname: Lattanzio
authors.affiliation: Department of Experimental and Clinical Sciences, "G. D'Annunzio" University and Foundation, Chieti, Italy. mdegidio@unich.it.
authors.forename: Maurizia
authors.initials: M
authors.lastname: D'Egidio
authors.affiliation: MediaPharma s.r.l., Via dei Vestini, 31, Chieti, Italy. annalisa.dirisio@libero.it.
authors.forename: Annalisa
authors.initials: A
authors.lastname: Di Risio
authors.affiliation: MediaPharma s.r.l., Via dei Vestini, 31, Chieti, Italy. mpiantelli@unich.it.|Department of Experimental and Clinical Sciences, "G. D'Annunzio" University and Foundation, Chieti, Italy. mpiantelli@unich.it.
authors.forename: Mauro
authors.initials: M
authors.lastname: Piantelli
authors.affiliation: Regina Elena Cancer Institute, Rome, Italy. natalipg2002@yahoo.it.
authors.forename: Pier Giorgio
authors.initials: PG
authors.lastname: Natali
authors.affiliation: MediaPharma s.r.l., Via dei Vestini, 31, Chieti, Italy. iacobell@unich.it.|Department of Experimental and Clinical Sciences, "G. D'Annunzio" University and Foundation, Chieti, Italy. iacobell@unich.it.
authors.forename: Stefano
authors.initials: S
authors.lastname: Iacobelli
mesh_terms: D000818:Animals; D000951:Antigens, Neoplasm / Q000378:metabolism*; D014408:Biomarkers, Tumor / Q000378:metabolism*; D002352:Carrier Proteins / Q000378:metabolism*; D049109:Cell Proliferation; D015179:Colorectal Neoplasms / Q000378:metabolism* / Q000473:pathology*; D015536:Down-Regulation; D005260:Female; D055785:Gene Knockdown Techniques; D020868:Gene Silencing; D006023:Glycoproteins / Q000378:metabolism*; D045325:HCT116 Cells; D057809:HEK293 Cells; D006801:Humans; D007150:Immunohistochemistry; D015552:Injections, Intralesional; D053208:Kaplan-Meier Estimate; D008819:Mice, Nude; D015999:Multivariate Analysis; D011379:Prognosis; D016896:Treatment Outcome; D023041:Xenograft Model Antitumor Assays; D051176:beta Catenin / Q000378:metabolism; D016326:Extracellular Matrix Proteins
chemical_list: D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D002352:Carrier Proteins; D006023:Glycoproteins; D051176:beta Catenin; C081856:LGALS3BP protein, human; D016326:Extracellular Matrix Proteins